Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Send this study to a contact
1
Your personal information
Your name
Your e-mail
Send me a copy
2
Your recipient's information
The name of your contact
Your contact email
3
Your message
Votre message
A 96-week, prospective, multicenter, randomised, double-blind, placebo-controlled, 2-parallel groups, Phase 3 study to compare efficacy and safety of masitinib 4.5 mg/kg/day versus placebo in the treatment of patients with primary progressive or relapse-free secondary progressive multiple sclerosis AB07002: 96 TÝŽDŇOVÁ, PROSPEKTÍVNA, MULTICENTRICKÁ, RANDOMIZOVANÁ, DVOJITO ZASLEPENÁ, PLACEBOM KONTROLOVANÁ ŠTÚDIA 3. FÁZY 2 PARALELNÝCH SKUPÍN, POROVNÁVAJÚCEJ ÚČINNOSŤ A BEZPEČNOSŤ MASITINIBU V DÁVKE 4,5 MG / KG / DEŇ PROTI PLACEBU PRI LIEČBE PACIENTOV S PRIMÁRNOU PROGRESÍVNOU SKLERÓZOU MULTIPLEX ALEBO SEKUNDÁRNE PROGRESÍVNOU SKLERÓZOU MULTIPLEX BEZ RELAPSOV https://www.kusajili.fr:443/Trial/CjYJcIVBU0OO2pT8vvqq3Q%24a-96-week-prospective-multicenter-randomised-double-blind-placebo-controlled-2-parallel-groups-phase-3-study-to-compare-efficac
I have read and accept the terms of use of the site and the Privacy Policy
Send your message